KRAS and lung cancer: This model has effectively linked histological phenotype with genetic mutation status, such as EGFR and KRAS mutations, and survival outcomes, including in LNM [591], thereby offering potential as an assistive diagnostic tool for mutation prediction and expediting treatment planning in lung cancer.